Purpose: Interest in targeted alpha-therapy has surged due to a-particles' high cytotoxicity. However, the widespread clinical use of this approach could be limited by on-/off-target toxicities. Here, we investigated the inverse electron-demand Diels-Alder ligation between an 225 Ac-labeled tetrazine radioligand and a trans-cyclooctene-bearing anti-CA19.9 antibody (5B1) for pretargeted a-radioimmunotherapy (PRIT) of pancreatic ductal adenocarcinoma (PDAC). This alternative strategy is expected to reduce nonspecific toxicities as compared with conventional radioimmunotherapy (RIT).
Introduction
Alpha-emitting radionuclides are of great interest in nuclear medicine due to their short particle range (50-100 mm) and high linear energy transfer ($80 keV/mm), traits that allow for the delivery of highly cytotoxic radiation to cancer cells (1, 2) . Actinium-225 ( 225 Ac; t 1/2 ¼ 10.0 d; 5.8 MeV a) has attracted a large share of this attention due to its long physical half-life and its "nanogenerator" status, producing a total of 4 a and 2 b À particles in its decay chain ( Fig. 1; ref. 3). These advantageous properties were explored for the treatment of acute myeloid leukemia in phase I/II clinical trials with a CD33-targeted 225 Ac-radioimmunoconjugate (HuM195; Lintuzumab), studies that underscored the potential of 225 Ac-radioimmunotherapy (RIT) for the treatment of systemic disease (4) (5) (6) . In addition, recent studies highlighted the potential of 225 Ac-RIT for the treatment of bulky tumors such as glioblastoma by targeting the vascular endothelium of the tumor (7, 8) . The radionuclide has also been conjugated to targeting vectors with more rapid pharmacokinetic profiles, including small-molecule inhibitors of prostate-specific membrane antigen (PSMA). To wit, salvation therapy with 225 Ac-PSMA-617 (100 kBq/bimonthly) has produced drastic complete response in patients with metastatic castration-resistant prostate cancer (9, 10) . Yet although 225 Ac-based radiotherapy is undeniably promising, its success is restricted by toxicities associated with the irradiation of healthy tissues following target engagement (on-target toxicities; e.g., xerostomia after 225 Ac-PSMA-617 therapy) or the nonspecific accumulation of the radiopharmaceutical (off-target toxicities; e.g., clearance organs).
Compromises between antitumor activity and toxicity must be made (10) . There is therefore an urgent unmet need for new strategies that can reduce the inherent toxicity of 225 Ac-RIT.
The inverse electron-demand Diels-Alder reaction (IEDDA) between tetrazine (Tz) and trans-cyclooctene (TCO) holds promise for a variety of applications, including radiochemistry (11, 12) . Our laboratories reported its potential for the synthesis of 225 Aclabeled radioimmunoconjugates (13) . The selectivity and rapidity of this reaction were investigated for in vivo pretargeting using TCO-bearing antibodies and Tz-containing radioligands (14) . This approach consists of 4 steps: (i) the administration of a TCO-bearing immunoconjugate; (ii) an interval period during which the immunoconjugate accumulates at the tumor and clears from the blood pool; (iii) the administration of a Tz-based radioligand; and (iv) the in vivo click reaction between the two components followed by the rapid clearance of excess radioligand. In essence, pretargeting seeks to combine the targeting properties of antibodies with the pharmacokinetic properties of small molecules. Pretargeted SPECT and PET imaging experiments yielded improved tumor-to-background activity concentration ratios as well as reduced absorbed radiation doses to normal tissues (15) (16) (17) . This approach was successfully applied to the pretargeted radioimmunotherapy (PRIT) of both pancreatic ductal adenocarcinoma (PDAC) and colorectal carcinoma with 177 Lu, a b À -emitting radionuclide (18, 19) .
The central hypothesis of this study is that leveraging the Tz/ TCO click ligation for 225 Ac-PRIT could ultimately mitigate toxicities while improving therapeutic indices. Herein, we report the use of the IEDDA reaction for 225 Ac-PRIT targeting carbohydrate antigen 19.9 (CA19.9; ref. 20) , a cell surface antigen overexpressed in PDAC. CA19.9 is one of the most widely studied pancreatic cancer biomarkers because it can be detected in patient serum. In addition, levels of serum CA19.9 can be correlated with the stage of the cancer as well as prognosis or treatment response (21) (22) (23) . With a 5-year survival rate lower than 8%, PDAC is uniformly lethal and lacks therapeutic options. The fully-human 5B1 antibody demonstrates exceptional affinity and high specificity for an extracellular epitope of CA19.9. Staining with 5B1 revealed a negative reactivity for most normal tissues, whereas samples of pancreatic tumors showed positive reactivity with a diffuse cytoplasmic staining and distinct cell membrane staining (24) . Early in 2016, the clinical potential of CA19.9 as a therapeutic target was investigated in patients with pancreatic cancers or CA19.9-positive malignancies (NCT02672917) via the weekly intravenous administration of 5B1 (MVT-5873). Two clinical trials with 5B1-based radioimmunoconjugates are currently ongoing: one in which the antibody is labeled with 89 Zr for PET imaging and a second in which the antibody is labeled with 177 Lu for RIT (NCT02687230 and NCT03118349). Therefore, the development of a 5B1-based approach to 225 Ac-PRIT could offer a new therapeutic approach for PDAC and has the potential to offer an interesting complementary perspective to these clinical investigations.
Materials and Methods
Details on antibody functionalization, radiolabeling, cell lines, and xenografts models are provided in the Supplementary Information. All animals were treated according to the guidelines approved by the Research Animal Resource Center and
Translational Relevance
Pancreatic cancer is on course to become the second leading cause of cancer-related deaths due to the paucity of treatment currently available. The development of novel targeted therapy strategies is therefore critical. Herein, we developed a pair of approaches to 225 Ac-based alpha-particle RIT centered on an antibody (5B1) with exceptional affinity and specificity for CA19.9, an antigen overexpressed in PDAC. The therapeutic efficacy and dose-limiting toxicity of conventional and pretargeted RIT are compared in subcutaneous and orthotopic murine models of PDAC. To the best of our knowledge, this is the first report detailing that 225 Ac-PRIT exhibits similar therapeutic effectiveness compared with conventional 225 Ac-RIT while simultaneously reducing hematotoxicity. These findings underscore the rationale for clinical trials of 225 Ac-PRIT for the treatment of PDAC. Institutional Animal Care and Use Committee at Memorial Sloan Kettering Cancer Center.
Biodistribution
Acute biodistribution studies were performed using healthy athymic nude mice bearing subcutaneous BxPC3 (CA19.9-positive) and MIAPaCa-2 (CA19.9-negative) xenografts (right flank, $100 mm 3 ). For the pretargeting strategy, 225 Ac-DOTA-PEG 7 -Tz or 225 Ac-DO3A-PEG 7 -Tz [18.5 kBq, 0.4 nmol (molar activity, MA ¼ 46 kBq/nmol); in 150 mL of 0.9 % NaCl þ 1.0 % BSA] were injected 72 hours following the administration of 5B1-TCO (200 mg; 1.32 nmol; in 200 mL of PBS). BSA is used in the formulation of the radioligands to prevent adsorption to the syringe plastic. Mice (n ¼ 5) were euthanized via CO 2 asphyxiation, and tissues of interest were collected. Each sample was counted for up to 10 min (24 hours after collection when secular equilibrium was reached) using a Wizard 2 automatic gamma counter set up to a 150 to 600 keV energy window. The calculation of %ID/g values is detailed in the Supplementary Information.
Cerenkov luminescence imaging
Imaging studies were performed on athymic nude mice bearing BxPC3 and MIAPaCa-2 tumors on the right and left flanks, respectively. Mice received an initial injection of 5B1-TCO (200 mg; in 200 mL of PBS) 72 hours prior the injection of 225 Ac-DOTA-PEG 7 -Tz [1.85 MBq, 26.0 nmol (MA ¼ 71 kBq/nmol); in 150 mL of 0.9 % NaCl þ 1.0 % BSA]. In this case, a large amount of the radiolabelled Tz was injected simply to achieve high Cerenkov signal. Mice were imaged up to 4 days after the injection of the radioligand and then euthanized. Organs were imaged ex vivo at two time points: 5 minutes after the organ collection and once secular equilibrium was reached (24 hours after sacrifice). Image acquisition, analysis, and quantification are described in the Supplementary Information.
Ex vivo analysis
Athymic nude mice xenografted with BxPC3 tumors were injected with either 225 Ac-DOTA-PEG 7 -5B1 [18.5 kBq, 8.6 mg (MA ¼ 308 kBq/nmol); in 150 mL of 0.9 % NaCl þ 1.0 % BSA] or 225 Ac-DOTA-PEG 7 -Tz [18.5 kBq, 0.4 nmol (MA ¼ 46 kBq/nmol); in 150 mL of 0.9 % NaCl þ 1.0 % BSA] at 72 hours post administration of 5B1-TCO (200 mg; in 200 mL of PBS). Mice were euthanized 1, 5, and 7 days after injection of the radiopharmaceutical. Mouse kidneys and tumors were embedded and sectioned during the 20 minutes that followed the animal sacrifice. Kidney and tumor sections were placed in a film cassette against a phosphor imaging plate (Fujifilm BAS-MS2325) for a first exposure time of 1 hour at -20 C. A second exposure (6 hours) with the same sections was performed once secular equilibrium was reached (24 hours after first exposure). Kidney sections were later stained with hematoxylin and eosin (H&E) for the differentiation of the cortex and medulla. Image analysis and quantification is described in the Supplementary Information.
Dosimetry
Dosimetry calculations are described in the Supplementary Information. Two hypotheses were used to take into account the redistribution of the 225 Ac daughters. In the first, 225 Ac and daughters decay at the site of 225 Ac decay (no redistribution). In this case, the total mean organ absorbed dose is then calculated as the sum of the mean absorbed doses calculated for 225 Ac, and each daughter multiplied by the weighting factor for the relevant decay branch (i.e., 2.2% for 209 Tl, 97.8% for 213 Po, and 100% for all others). In the second hypothesis, we postulate that the 221 Fr and 217 At daughters decay at the site of 225 Ac decay due to their short physical half-lives, but that the extended half-life of 213 Bi allows significant redistribution. Here, as a conservative (worst-case) dose projection, the whole-body residence time of the daughters from 213 Bi to 209 Pb is assumed to occur entirely in the kidneys. The total mean absorbed dose in all organs except the kidneys is calculated as the sum of mean absorbed dose calculated for 225 Ac and its daughters up to 217 At. The total mean absorbed dose in the kidneys is calculated as stated previously.
In vivo therapy in subcutaneous xenografts
Tumor volumes were monitored with a Peira TM900 imaging device (Peira, Belgium). After the initial tumor measurement, mice were randomized into cohorts (n ¼ 8) so that the mean tumor volume of each cohort was approximately equal. The study was then blinded so that the volume measurements were not biased. One day after randomization, mice receiving PRIT were injected with 5B1-TCO (200 mg; in 200 mL of PBS). Seventy-two hours later, mice were injected with the appropriate radioactive payload: either 225 Ac-DOTA-PEG 7 -5B1 (9.25, 18.5, or 37 kBq) for conventional RIT or 225 Ac-DOTA-PEG 7 -Tz (9.25, 18.5, or 37 kBq) for PRIT. The control cohorts were injected with either vehicle (0.9 % sterile saline), 5B1-TCO alone (200 mg; in 200 mL of PBS), 225 Ac-DOTA-PEG 7 -Tz alone (37 kBq), or 225 Ac-DOTA-PEG 7 -IgG (37 kBq; IgG from human serum, Sigma). Tumor volume and body weight were measured biweekly until 120 days or until mice reached the set volume endpoint (>2,000 mm 3 ). Mice were monitored for outward signs of toxicity, including lethargy, loss of appetite, or disseminated intravascular coagulation.
In vivo therapy in orthotopic xenografts
Pancreatic tumor burden was monitored by in vivo bioluminescence imaging (BLI). Fifteen days after implantation, the radiance in each tumor was measured. Mice were randomized in five different cohorts (n ¼ 10) so that the average radiance was almost equal between the cohorts. One day after randomization, mice receiving pretargeted RIT were injected with 5B1-TCO (200 mg; in 200 mL of PBS). Seventy-two hours later, mice were injected with the appropriate radioactive payload; either 225 Ac-DOTA-PEG 7 -5B1 (18.5 or 37 kBq) for conventional RIT or 225 Ac-DOTA-PEG 7 -Tz (18.5 or 37 kBq) for PRIT. The control cohort was injected with vehicle (0.9 % sterile saline). Tumor radiance and body weight were measured weekly until 103 days. Mice were monitored for outward signs of toxicity, including lethargy, loss of appetite, or disseminated intravascular coagulation. Mice were sacrificed once the tumor burden covered >50 % of the abdomen or when mice showed significant weight loss.
Hematologic toxicity and nephrotoxicity
Blood samples ($50-100 mL, n ¼ 3-5) were collected weekly via retroorbital blood draws and analyzed with an Hemavet 950 (Drew Scientific). Twenty parameters were recorded, including red blood cell count, hematocrit, white blood count, and platelet counts. Mice kidneys were collected when the mice reached endpoint and kept in 10% neutral-buffered formalin at room temperature. Once the therapeutic study was closed, kidneys were processed routinely for histology, embedded in paraffin, sectioned, stained with H&E, and submitted to a board-certified veterinary pathologist for evaluation.
Statistical analysis
All data are represented as mean value AE standard deviation (with n ¼ 5-10, unless otherwise noted). The sample sizes were selected taking into account both statistical consideration and the exigencies of funding. The significance analyses were performed using GraphPad Prism software 7.0, employing unpaired twotailed t tests, multiple t tests, and logrank Mantel-Cox test as detailed in figure legends. A P value of <0.05 was considered significant. When appropriate, a conservative correction (Bonferroni) was made for the multiple hypotheses being tested to control the false-positive rate and provide confidence that positive findings are true signals.
Results

Ac-PRIT offers an improved biodistribution profile compared with conventional RIT
To evaluate the potential of 225 Ac-PRIT, we first performed biodistribution studies and compared the in vivo data with that of a directly-labeled radioimmunoconjugate ( Fig. 2A ). For conventional RIT, 5B1 was radiolabeled with 225 Ac using a two-step protocol published by our groups (13) . For the pretargeting technique, 5B1 was first functionalized with TCO via the incubation of the antibody with an NHS-bearing variant of TCO (18) and then injected 72 hours prior to the administration of an 225 Aclabeled Tz radioligand: 225 Ac-DOTA-PEG 7 -Tz ( Fig. 2A) .
The biodistribution of 225 Ac-DOTA-PEG 7 -Tz was assessed in healthy nude mice without the preinjection of 5B1-TCO (Supplementary Fig. S1A ). As expected, the radioligand is rapidly excreted. The liver (3.7 AE 0.6 %ID/g) and kidneys (1.9 AE 0.2 %ID/g) display the highest activity concentrations 4 hours after administration. A comparison between the biodistribution of the directly-labeled 225 Ac-DOTA-PEG 7 -5B1 (18.5 kBq, 0.06 nmol) radioimmunoconjugate and the 5B1-TCO/ 225 Ac-DOTA-PEG 7 -Tz (1 nmol/18.5kBq, 0.4 nmol) pretargeting approach was performed in mice bearing subcutaneous BxPC3 (CA19.9-positive) and MIAPaCa-2 (CA19.9-negative) xenografts ( Fig. 2B ; Supplementary Fig. S1C and S1D). Both methods produce high activity concentrations in the CA19.9-positive tumors up to 10 days after injection of the 225 Ac-constructs. At early time points, the pretargeting approach results in lower tumoral uptake (4.6 AE 3.3 %ID/g; 4 hours after injection of 225 Ac-DOTA-PEG 7 -Tz) compared with the directly labeled antibody (15.4 AE 3.5 %ID/g; 4 hours after injection of 225 Ac-DOTA-PEG 7 -5B1). However, the in vivo ligation between circulating 5B1-TCO immunoconjugates and 225 Ac-DOTA-PEG 7 -Tz allows for the accumulation of 255 Ac-DOTA-PEG 7 -5B1 conjugates in the blood and their subsequent delivery to the tumor site. Consequently, 3 days following the administration of the 225 Ac-labeled constructs, the tumoral uptake values of the two methods are comparable: 31.1 AE 21.4 %ID/g for 225 Ac-DOTA-PEG 7 -5B1 and 29.6 AE 6.6 %ID/g for 5B1-TCO/ 225 Ac-DOTA-PEG 7 -Tz. Importantly, no significant decrease in tumor volume was observed over the course of the biodistribution experiments, confirming that any changes in activity concentration were the result of the differential uptake of the radiopharmaceuticals themselves and not changes in the tumor size ( Supplementary Fig. S1B ). The activity concentrations in the MIAPaCa-2 xenografts are far lower compared with the BxPC3 xenografts: 5.3 AE 2.7 %ID/g for 225 Ac-DOTA-PEG 7 -5B1 and 2.2 AE 0.6 %ID/g for 5B1-TCO/ 225 Ac-DOTA-PEG 7 -Tz. This result highlights the specificity of the 5B1 antibody for CA19.9 and reinforces the sensitivity of pretargeting in vivo.
Critically, the PRIT approach yields significantly lower activity levels in the blood (7.7 AE 1.7 %ID/g) at 4 hours after injection compared with the directly-labeled radioimmunoconjugate (16.7 AE 2.3 %ID/g). Moreover, the PRIT strategy produces significantly lower activity concentrations in healthy organs, including the liver, spleen, and bone. To wit, the liver activity concentrations are 3-fold lower for the PRIT (1.5 AE 0.1 %ID/g; 10 days p.i.) compared with the directly-labeled antibody (5.8 AE 2.6 %ID/g; 10 days p.i.). Tumor-to-organ activity concentration ratios confirm the superior performance of PRIT ( Supplementary  Tables S2 and S3 ). A higher tumor-to-liver activity concentration ratio is observed 10 days following the administration of 225 Ac-DOTA-PEG 7 -Tz (27.0 AE 15.8) compared with 225 Ac-DOTA-PEG 7 -5B1 (5.6 AE 3.1). Similarly, higher tumor-to-spleen and tumor-to-bone ratios are noted as well. Biodistribution studies with 225 Ac-labeled radioimmunoconjugates were also performed using a different chelator (DO3A; Supplementary Fig. S2A and S2B) as well as a different vector: the huA33 antibody that targets the A33 antigen, a biomarker of colorectal cancer (Supplementary Fig. S2C and S2D ). Comparable biodistribution trends are observed in both cases, clearly illustrating the modularity of this approach. Our data with the 5B1 antibody are particularly promising, because the pretargeting method yields tumoral uptake values similar to those produced using the directly-labeled antibody while reducing the activity concentrations in the blood and healthy organs. This is especially compelling in the context of RIT, because these results suggest that PRIT could significantly reduce nonspecific toxicity.
Both the weight and the uptake of the radiolabeled constructs in the spleen were monitored as indicators of myelosuppression and especially leukopenia ( Supplementary Fig. S3 ). The splenic activity concentrations for both methodologies decrease over the course of the biodistribution study, indicating good clearance of 225 Ac-constructs. However, in the case of the conventional RIT, the weight of the organ significantly decreases from 4 hours to 10 days after administration (P 0.01). In other cases, decreases in the spleen size were observed in mice administered immunosuppressive treatments (25) . It follows that this could be an early sign of myelosuppression in the mice treated with the conventional RIT. No statistically significant decrease in spleen weight is observed with the pretargeting strategy.
Cerenkov luminescence imaging for 225 Ac and radioactive daughters' biodistribution monitoring
Cerenkov radiation emanates in response to the decay of a large variety of radionuclides. In a phantom imaging study evaluating the yield of Cerenkov radiation with a range of positron-, b À -, and a-emitting radioisotopes-including 18 F, 64 Cu, 89 Zr, 124 I, 131 I, and 225 Ac-the latter produced the most intense radiation (26) . 225 Ac-based Cerenkov emissions are postulated to arise from the b-decay of three of its daughters: 213 Bi, 209 Tl, and 209 Pb. Due to the limited tissue penetration of optical-frequency photons, Cerenkov imaging (intraoperative settings aside) has limited utility with radionuclides that decay via "imageable" emissions (e.g., positrons or gamma rays); however, it can be valuable for monitoring the biodistribution of radiopharmaceuticals labeled with nuclides (e.g., 225 Ac) that cannot be imaged effectively using Pretargeting RIT as compared with conventional RIT. A, A schematic representation of the two administration methods. For conventional RIT, xenografted mice are i.v. injected with the desired directly radiolabeled antibody. For PRIT, mice are injected a first time with an antibody-TCO conjugate, which slowly accumulates at the tumor and clears from the blood. Three days later, the mice are injected with the 225 Ac-labeled Tz radioligand. The Tz-based radioligand either reacts in vivo with the TCO-bearing antibody to form radioimmunoconjugates or is cleared rapidly from the system. In both techniques, therapeutic radiation is delivered to the tumor but also results in off-target toxicity, such as hematotoxicity. B, Comparison of the in vivo biodistribution in BxPC3 (CA19.9-positive) and MIAPaCa-2 (CA19.9-negative) tumor-bearing athymic nude mice of 225 Ac-DOTA-PEG 7 -5B1 (18.5 kBq, 8.6 mg, 0.06 nmol) and 5B1-TCO þ 225 Ac-DOTA-PEG 7 -Tz (200 mg, 1.32 nmol þ 18.5 kBq, 0.5 mg, 0.4 nmol) up to 10 days after injection. Only major organs are represented. Error bars represent the SD (n ¼ 5). Multiple t tests were performed, and a Bonferroni correction was applied for the calculation of adjusted P values. ÃÃÃ adjusted P 0.001; n.s., nonsignificant. C, Comparison of the tumor-to-tissue activity concentration ratios for 225 Ac-DOTA-PEG 7 -5B1 and 5B1-TCO/ 225 Ac-DOTA-PEG 7 -Tz. Error bars represent the SD (n ¼ 5). traditional technologies. Cerenkov imaging was used to study the biodistribution of the a v b 3 integrin-targeted radiotherapeutic 225 Ac-DOTA-(RGDyK) in a mouse model of human glioblastoma (27) . Yet in the aforementioned study, Cerenkov imaging limitations were clearly on display, as the injected dose (1.9 MBq) was well over the determined MTD, and the mice were only imaged up to 24 hours after injection. Cerenkov imaging with 225 Ac-radioimmunoconjugates is therefore a major challenge due to the high risk of lethal toxicity. However, the improved biodistribution profile obtained using 225 Ac-PRIT allowed us to attempt Cerenkov imaging in vivo.
Mice bearing bilateral BxPC3 and MIAPaCa-2 tumor xenografts were injected with 5B1-TCO (1 nmol) and then-72 hours later-225 Ac-DOTA-PEG 7 -Tz (26 nmol). To ensure that sufficient signal would be observed, a high dose of 225 Ac-DOTA-PEG 7 -Tz was injected (1.9 MBq). Cerenkov imaging performed up to 4 days following the administration of 225 Ac-DOTA-PEG 7 -Tz (Fig. 3A ) revealed persistent and increasing radiance (p/sec/cm 2 /sr) in BxPC3 tumors (10,600 AE 1,000 at 4 hours p.i. and 22,100 AE 3,600, at 96 hours p.i.), whereas the radiance in the remaining body (33,200 AE 4,000 at 4 hours p.i. and 13,400 AE 1,300 at 96 hours p.i.) and the MIAPaCa-2 xenografts (7,100 AE 1,200 at 4 hours p.i. and 3,500 AE 600 at 96 hours p.i.) both decrease over time ( Supplementary Fig. S4A ). Not surprisingly, Cerenkov imaging confirms the biodistribution profile of PRIT as well as the specificity for CA19.9.
Ex vivo Cerenkov imaging was performed at two time points: immediately following the sacrifice of the animals and again following the establishment of secular equilibrium. In a radioactive decay chain in which the parent radionuclide (i.e. 225 Ac) has a much longer half-life than its radioactive daughter, secular equilibrium is defined as the limiting case (in time) in which the rate of decay of the daughter and parent becomes equivalent ( Supplementary Fig. S5 ). In the case of 225 Ac, secular equilibrium is reached 24 hours after disruption of the equilibrium state. Imaging immediately following the euthanasia of the animals shows higher activity concentrations of the radioligand in the BxPC3 xenografts (36,200 AE 6,900 p/sec/cm 2 /sr) compared with the MIAPaCa-2 tumors (4,900 AE 800 p/sec/cm 2 /sr; Fig. 3B ). At this time point, Cerenkov radiation is also observed in the liver and kidneys. However, once secular equilibrium is reached-24 hours following euthanasia-a clear decrease in the kidneys radiance is observed. The radiation quantification in regions of interest drawn around the organs confirms that the kidneys are the only organs with a significant change in radiance once secular equilibrium is reached: 16,400 AE 2,300 p/sec/cm 2 /sr at 4 days after injection compared with 4,900 AE 800 p/sec/cm 2 /sr at secular equilibrium (P 0.001; Fig. 3C ). This phenomenon results from the presence of nonequilibrium daughters in the kidneys. The strong recoil energy associated with the emission of a-particles (about 100 keV) is higher than the binding energy of any chemical bond. As a result, 225 Ac decay daughters are released from the chelator and can redistribute within the body (28) . Depending on the daughters' physical half-lives as well as their affinity for certain organs, this redistribution can result in toxicity to healthy tissues. In the case of 225 Ac, two decay daughters-221 Fr and 213 Bi-with intrinsic affinity for the kidneys have half-lives sufficiently long to allow for their redistribution. We therefore hypothesize that the higher kidney radiance immediately following necropsy relative to that observed at secular equilibrium arises from the presence of free 221 Fr, 213 Bi, as well as their b-emitting daughters.
The evaluation of 225 Ac daughters' redistribution in the different regions of the kidney was further pursued via autoradiography following the administration of both the conventional RIT and PRIT strategy. To this end, two autoradiographic exposures of kidney sections were obtained 1, 5, and 7 days after the injection of the radiopharmaceuticals. The first exposure was performed in the 20 minutes that followed euthanasia, and the second was performed 24 hours later (once secular equilibrium was reached). A qualitative comparison of the autoradiographic exposures shows stronger signal intensity in the kidney cortex at secular equilibrium compared with the first exposure, indicating the accumulation of 225 Ac in this kidney area (Fig. 3D ). This trend is observed for both 225 Ac-DOTA-PEG 7 -5B1 and 5B1-TCO/ 225 Ac-DOTA-PEG 7 -Tz. As noncoordinated actinium mainly distributes to the liver and bone (29) , and unreacted 225 Ac-DOTA-PEG 7 -Tz is excreted in a few hours via the kidneys, we hypothesize that the 225 Ac observed in the kidneys 3 days following the injection of the radioligand is present in the form of its antibody conjugate. In contrast, the qualitative analysis of the autoradiography shows a Table 2 . Extrapolation of pretargeted RIT dosimetry to humans; Absorbed dose estimations for the ICRP 89 adult man calculated from the biodistribution data of 5B1-TCO/ 225 Ac-DOTA-PEG 7 -Tz in mice bearing BxPC3 xenografts; Full dosimetry data are provided in Supplementary Table S16 5B1-TCO þ 225 Ac-DOTA-PEG 7 decrease in signal intensity between the two exposures in the renal medulla, highlighting the presence of nonequilibrium daughters. Quantitative analysis of these images confirms the qualitative observations ( Supplementary Fig. S4B) . The difference between the cortex-to-medulla mean intensity ratio at the first (2.5 AE 0.7) and second (4.1 AE 0.9) exposure of the slices obtained 7 days after injection of 225 Ac-DOTA-PEG 7 -Tz further reinforces the presence of nonequilibrium daughters in the medulla ( Supplementary Fig.  S4B ). It is important to note that both administration methods lead to the same scenario: neither method stands out in term of limiting the redistribution of 225 Ac's daughters. Similarly, two autoradiographs of tumor sections were collected 3 days after injection of PRIT and RIT. A qualitative analysis of the signal localization and intensity between the postmortem and the secular equilibrium exposure revealed a good correlation (Supplementary Fig. S4C ). This observation highlights that within the tumor, the activity is present in the form of 225 Ac and its equilibrium daughters. 
Mouse dosimetry and projection to human patients
The redistribution of 225 Ac's daughters has obvious implications for dosimetry. However, such calculations require the quantitative assessment of the time-dependent biodistribution of each daughter, and the measurement thereof is currently met with wellrecognized limitations (e.g., short physical half-life, limited detection technique for a-particle). The Committee on Medical Internal Radiation Dose has recommended that a potential "conservative (worst-case) scenario" be assessed in such circumstances (30) . Here, we adopt this approach for two different hypothetical scenarios. In the first, all of 225 Ac's daughters decay at the site of the original 225 Ac decay. Given this hypothesis, 225 Ac-DOTA-PEG 7 -5B1 and 5B1-TCO/ 225 Ac-DOTA-PEG 7 -Tz produce similar mean absorbed doses in the tumor: 1377 Gy/MBq and 1994 Gy/MBq, respectively ( Table 1 ; Supplementary Table S4 ). For all organs, the pretargeting method results in higher therapeutic indexes (>21). Indeed, the spleen, liver, and bone have therapeutic indexes 4, 5, and 7 times higher, respectively, with the PRIT strategy compared with the conventional RIT (Table 1 ). In this scenario, a 50 kBq dose of 225 Ac-DOTA-PEG 7 -Tz would result in a mean absorbed dose of >100 Gy at the tumor site, above the threshold for a meaningful response in the case of solid tumors (31) . This injected activity would also result in a kidney mean absorbed dose of 2.8 Gy, below the radiosensitivity threshold of this organ (15) (16) (17) (18) (19) (20) refs. 31, 32) . With mean absorbed doses of 120.3 Gy/MBq and 82.6 Gy/MBq for RIT and PRIT, respectively, the blood is expected to be the dose-limiting organs in the case of the first hypothesis. In the second (worst-case) hypothesis, we postulate the redistribution of all the residence time contributed by 213 Bi and its progeny to the kidneys. Put differently, we assume that all of the 213 Bi nuclei immediately relocate to-and subsequently decay in-the kidneys. In this case, we notice a decrease of 32% in the tumor mean absorbed dose of both administration methods. Consequently, the kidney therapeutic index is affected as well, dropping to 0.9 and 1.9 for 225 Ac-DOTA-PEG 7 -5B1 and 5B1-TCO/ 225 Ac-DOTA-PEG 7 -Tz, respectively. In this scenario, the injected activity for therapeutic studies should be <18 kBq to ensure that the kidney mean absorbed dose remains below their radiosensitivity threshold (20 Gy).
The extrapolation of these data to humans consolidates the superior dosimetric profile of the pretargeting approach. Indeed, the mean absorbed doses to most major organs are lower for the pretargeting method (Table 2 ; Supplementary Table S5 -S7). Depending on the hypothesis, the dose-limiting organ for PRIT is either the bone marrow (hypothesis #1) or the kidneys (hypothesis #2; Table 2 ). Assuming an MTD of 1 Sv RBE5 for the red marrow and 27 Sv RBE5 for the kidneys, the maximum-tolerated adminis-tered activity would be approximately 10.4 MBq for the first hypothesis and 5.3 MBq for the second hypothesis (Table 2; ref. 33 ). Dose-limiting organs are similar with conventional RIT ( Supplementary Table S8 ).
PRIT results in prolonged survival and reduced toxicity
The next step in our investigation was clear: longitudinal therapy studies. Based on the aforementioned dosimetry calculations, the maximum injected activity was set to 37 kBq (Table 1) . With this amount of injected activity, the dose delivered to the tumor with conventional RIT and PRIT was estimated to be between 63 and 75 Gy, slightly below the threshold (100 Gy) for a meaningful response in the case of solid tumors, while simultaneously limiting kidney toxicity. Mice bearing subcutaneous BxPC3 tumors (n ¼ 8 per cohort) were injected with 3.7, 18.5, and 37.0 kBq of conventional RIT and PRIT to establish a dosedependent response. Control groups include mice injected with saline (vehicle), 5B1-TCO alone, 225 Ac-DOTA-PEG 7 -Tz alone, and 225 Ac-DOTA-PEG 7 -IgG. Survival analysis suggests therapeutic efficacy in cohorts receiving 18.5 and 37 kBq compared with control groups (P values < 0.01; Supplementary Fig. S6 and Supplementary Table S9 ). Median survival for the group treated with 37 kBq of 225 Ac-DOTA-PEG 7 -5B1 (107.5 days) and the cohort treated with 37 kBq of 5B1-TCO/ 225 Ac-DOTA-PEG 7 -Tz (114.5 days) suggests a similar therapeutic efficacy between conventional RIT and PRIT at the highest dose (P ¼ 0.17; Fig. 4A ; Supplementary Table S9 ).
The body weight progression for both groups receiving the highest dose of conventional RIT and PRIT deviates from the control group from day 3 to day 21 after the administration of the radiotherapeutic (Fig. 4B) . However, the maximum average weight loss did not exceed 14%. All mice recovered their original body weight over a 3-week time period. One mouse out of the 8 treated with 37 kBq of 225 Ac-DOTA-PEG 7 -5B1 was euthanized after 18 days due to disseminated intravascular coagulation. The pathologic evaluation of this mouse revealed marked depletion of all the hematopoietic precursors in the bone marrow (Fig. 4C) . Acute hemorrhages were observed on the level of the skin and correlate with the marked thrombocytopenia due to the absence of megakaryocytes in the bone marrow. No such observations were made with the RIT and PRIT cohorts that had been injected with the lower doses. Hematoanalysis performed on separate mice cohorts (n ¼ 5) receiving the highest dose treatment (37 kBq) highlights the higher hematotoxicity of RIT compared with PRIT and correlates with the anticipated higher absorbed dose to the blood uncovered in the RIT mouse dosimetry. Marked decreases Figure 5 .
Conventional and pretargeted RIT studies in mice bearing orthotopic xenografts A, Percent survival as function of time after RIT injection. Mice were sacrificed when the bioluminescent signal covered >50% of abdomen or upon significant body weight loss (>20%). Survival data reflect the progression of primary orthotopic tumors and systemic radiotoxicity, such as disseminated intravascular coagulation (n ¼ 10/cohort). B, Correlation between the initial tumor radiance and survival. Mice dying from radiotoxicity were excluded from this analysis. Pearson correlation coefficients (r) were calculated assuming a Gaussian distribution of the sample. C, Change in body weight and hematologic parameters during the course of RIT. Body weight (n ¼ 10) was monitored biweekly, and complete blood counts (n ¼ 5) were monitored weekly using the same animal cohorts as for survival monitoring. Twenty parameters for blood analysis were recorded, and four are represented: red blood cell counts, hematocrit, WBC counts, and platelet counts. Values are represented as means, and error bar represents the SD. RBC, red blood cell; HCT, hematocrit; WBC, white blood cell; PLT, platelets. D, H&E staining of mice kidneys after 225 Ac-RIT at the highest-dose regimen. Left images are representative areas of the kidney of a mouse treated with 225 Ac-DOTA-PEG 7 -5B1 (37 kBq) that shows normal morphology after therapy. Middle images are representative areas of a kidney of a mouse treated with 225 Ac-DOTA-PEG 7 -5B1 (37 kBq) that presents minimal cortical tubular degeneration and necrosis (focal, unilateral). Left images are representative areas of a kidney of a mouse treated with 5B1-TCO/ 225 Ac-DOTA-PEG 7 -Tz (37 kBq) that presents mild cortical tubular degeneration (multifocal, bilateral). Yellow highlighted areas show abnormal tubules. Scale bars, 1,000 mm (low magnification) and 50 mm (high magnification). in hematocrit and red blood cell count are observed between days 10 and 66 with 225 Ac-DOTA-PEG 7 -5B1 (37 kBq); during this same period, the values for the cohorts treated with PRIT remained similar to those of the control groups (Fig. 4B ). For the cohorts treated with 225 Ac-DOTA-PEG 7 -5B1 (37 kBq) and 5B1-TCO/ 225 Ac-DOTA-PEG 7 -Tz (37 kBq), white blood cell (WBC) counts show a maximum decrease between days 3 and 30 of up to 29% and 40% of the original value, respectively (Fig.  4B) . However, the PRIT-treated mice recovered their WBC counts faster than those receiving conventional RIT: 45 days versus 66 days ( Supplementary Fig. S7 ). Platelet counts likewise show a marked decreased in the case of conventional RIT, with a recovery to original values 66 days after treatment administration (Fig. 4B) . A decrease in platelets has been shown to correlate with bone-marrow radiation absorbed dose in a study with a 177 Lu-labeled antibody specific for prostate-specific membrane antigen (34) . In light of this, our results suggest that PRIT is a promising strategy to reduce radiation-induced myelotoxicity.
To establish this finding in a more clinically relevant tissue microenvironment, therapy studies were performed in mice inoculated orthotopically with BxPC3-luc cells. Twenty days following inoculation, the mice were treated with conventional and pretargeted RIT (18.5 kBq and 37.0 kBq). Both cohorts treated with the highest doses (37 kBq) show prolonged median survival compared with the control groups (Fig. 5A ). PRIT (37 kBq) produces a significantly superior median survival of 67.5 days compared with 28.5 days for the vehicle-only control group (P < 0.001). Despite a median survival of 60.0 days, conventional RIT (37 kBq) does not demonstrate a significant prolonged survival compared with the vehicle-only control due to the loss of four animals at the beginning of the study: two from rapid tumor progression and two from disseminated intravascular coagulation. Surprisingly, treatment with the lower dose (18.5 kBq) results in significant prolonged survival (P < 0.05) in the case of conventional RIT (46 days) but not in the case of PRIT (32 days; Supplementary Fig. S8A and Supplementary Table S10 ). The survival of individual animals was shown to correlate with the initial bioluminescent signal (radiance) of its tumor (Fig. 5B ). The mice with initial tumor radiance below 100 Â 10 7 p/sec/cm 2 /sr all show survival superior than 50 days, highlighting the strong therapeutic potential of 225 Ac for small neoplasms.
As previously observed with the subcutaneous model, hematotoxicity was observed in the 37 kBq conventional RIT cohort. In this cohort, 2 mice out of 10 (20 %) had to be sacrificed at day 8 due to disseminated intravascular coagulation. No such observation was made in the PRIT cohorts. Complete blood count analysis confirmed a more severe decrease in the WBC and platelet counts between days 3 and 45 after the administration of conventional RIT compared with PRIT ( Fig. 5C ). Long-term nephrotoxicity was evaluated via the pathologic evaluation of the kidneys of the 6 longest surviving mice treated with the higher doses. For each administration method, three kidneys out of six (50%) demonstrated mild cortical tubular degenerative changes and/or evidence of minimal to mild cortical tubular necrosis ( Fig. 5D ; Supplementary Table S11 ). These changes are hypothesized to be the result of the radiopharmaceuticals, as such observations are not typically reported in mice of this strain and age. However, the lesions were minimal to mild, affected a very small proportion of the tubules, and likely did not affect renal function: there was no significant evidence of elevation in urea and creatine in the blood chemistry performed (P > 0.05; Supplementary Fig. S8B ). As these observations were only reported in the kidney cortex, we hypothesize that these morphologic changes were not related to 225 Ac's daughters redistribution, because it was previously demonstrated that these radionuclides primarily localize in the kidneys medulla. These pathology findings correlate with the comparable absorbed doses to the kidney obtained with both administration methods and highlight the accuracy of our dosimetry methodology.
Discussion
Herein, we have demonstrated that PRIT with 5B1-TCO and 225 Ac-DOTA-PEG 7 -Tz is as effective as conventional RIT while simultaneously reducing hematotoxicity. Biodistribution studies carried out with both RIT and PRIT highlight the promise of 225 Acbased pretargeting in terms of tumoral uptake and clearance. Previous pretargeting studies carried out with short-lived, positron-emitting isotopes were often associated with low tumoral activity concentrations ( 6 %ID/g; refs. [15] [16] [17] . In contrast, pretargeting with the long-lived isotope 225 Ac produced tumoral activity concentrations as high as 41.7 AE 24.0 %ID/g 10 days after the radioligand administration. This increase in tumoral uptake is most likely the result of click reactions between circulating 5B1-TCO and the 225 Ac-labeled Tz, forming 225 Ac-labeled radioimmunoconjugates that slowly accumulate within tumor tissue. Our group has already reported similar trends in 177 Lu-PRIT, with tumor activity concentrations approaching 20 %ID/g (18) . It is important to note that the structure of Tz-based radioligands can strongly influence their pharmacokinetic profiles and uptake in the tumor and other tissues (35) ; this is the most likely cause for the differences observed between the tumoral activity concentrations produced by 177 Lu-and 225 Ac-PRIT. Importantly, 225 Ac-PRIT resulted in increased tumor-to-tissue activity concentration ratios, a trait which is critical in limiting nonspecific toxicity. Finally, the modularity of this PRIT strategy is reinforced by biodistribution studies carried out with another chelator (DO3A) and another antibody-antigen system (huA33/A33).
One major limitation of a-radiotherapy preclinical development is the lack of imaging techniques. However, 225 Ac's daughters' Cerenkov radiation as well as improved biodistribution profile facilitated by pretargeting allowed us to attempt 225 Acbased Cerenkov radioimmunoimaging. Although in vivo Cerenkov imaging confirmed the pharmacokinetic profile of our pretargeting system, ex vivo imaging provided us with valuable insight into the redistribution of 225 Ac's nonequilibrium daughters. Imaging of the organs postmortem at two different time points highlighted the presence of nonequilibrium daughters in the kidneys, a result that had only been previously reported using g-ray spectroscopy and autoradiography (36) . The short half-lives of the daughters of 225 Ac can make the data acquisition with these latter techniques cumbersome; Cerenkov imaging, in contrast, enabled the screening of 8 tissues in the 5 minutes following euthanasia and therefore constitutes a valuable tool for the preclinical evaluation of 225 Ac-based radiopharmaceuticals.
The accumulation of 225 Ac's daughters in the kidneys medulla was later confirmed by autoradiography. The radionuclides' redistribution is the result of the strong recoil energy associated with a-particles emission (about 100 keV) and constitutes a major concern for the clinical translation of a-therapies. Strategies to control the fate of these daughter radionuclides include the internalization of the nanogenerator (3), the local administration of the radiopharmaceutical (37, 38) , and 225 Ac encapsulation within nanocarriers (39, 40) . Unfortunately, these methods come with limitations, such as low internalization rates and poor biodistribution profiles. Another approach, which was translated clinically, relies on the use of diuretics to accelerate the excretion of the daughters (41) . Along these lines, furosemide and spirolactone are currently used in clinical trials with both 225 Ac-and 212 Pb-labeled radioimmunoconjugates (6, 42) . Generally speaking, efficient pretargeting strategies employ noninternalizing antibody-antigen systems; however, this necessarily facilitates the redistribution of 225 Ac's daughters. It was therefore critical to ensure that the redistribution of 225 Ac's daughters to the medulla of the kidney was not generating off-target toxicities. The therapy studies carried out in our study focused particularly on late nephrotoxicity and its correlation with the daughters' redistribution. Mild cortical tubular degeneration and necrosis was observed with both administration methods but did not result in the impairment of the renal function. These morphologic changes can be attributed to the 225 Ac-labeled constructs but unlikely related to 225 Ac's radioactive daughters redistribution because only the kidney cortex was affected. Dosimetry calculations based on two different hypotheses were performed in order to account for the redistribution and decay of daughter radionuclides. The extrapolation of murine data to humans confirms the superiority of the pretargeting approach, which boasts improved mean absorbed doses in most organs. Indeed, the MTDs determined with the pretargeting approach are higher or in the same range as the currently administered activities in the clinical trials focused on 225 Ac-Lintuzumab (18.5 kBq/kg; ref. 6) and 225 Ac-PSMA-617 (100 kBq/kg; ref. 9).
The mouse dosimetry data allowed us to determine a range of suitable doses for longitudinal therapy studies. As a proof of concept, therapeutic studies were first conducted in mice bearing subcutaneous CA19.9-positive PDAC xenografts. Therapeutic efficacy was observed in the cohorts receiving the two highest doses of both RIT and PRIT. The median survival times of the two administration methods were similar at the highest injected activity (37 kBq). However, hematotoxicity was significant in the case of conventional RIT, with one mouse dying of disseminated intravascular coagulation and marked decreases in hematologic parameters such as RBC, HCT, WBC, and PLT across the entire cohort. Similar observations were made in an orthotopic tumor model. Hematotoxicity was therefore the limiting factor for conventional RIT, a finding that correlates with the higher absorbed dose to the blood extrapolated from our biodistribution. In this study, the MTD was not reached with 225 Ac-PRIT, and higher injected activities should be investigated to increase the therapeutic benefit of PRIT. The use of an immunocompetent mouse model should also be considered in order to maximize benefits from the radiation-induced immune response (the abscopal effect).
In sum, the 225 Ac-based strategy for PRIT reported here facilitates (1) the delivery of radioactive payloads to tumor sites while reducing the mean absorbed dose to healthy tissues and (2) enables prolonged survival and reduced hematotoxicity in subcutaneous and orthotopic models of PDAC compared with conventional RIT. The development of PRIT for a-therapy complements the two on-going 5B1-based clinical trials for the diagnosis ( 89 Zr) and b-therapy ( 177 Lu) of PDAC and has the potential to extend the population of patients eligible for CA19.9-targeted radiotherapy to include those with residual metastatic lesions as well as patients that develop resistance to b-therapy. Future studies will assess the ability of 225 Ac-PRIT to delay tumor growth and evaluate the MTD with fractionated doses. A comparison of the potential of aand b-PRIT in different mouse models will also allow us to further tailor this treatment according to tumor burden and phenotype.
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